Funding for this research was provided by:
Academy of Finland (295741, 314383, 272376, 266286, 317332)
Juho Vainion Säätiö
Novo Nordisk (NNF17OC0027232, NNF10OC1013354)
Suomen Lääketieteen Säätiö
Signe ja Ane Gyllenbergin Säätiö
Sigrid Juséliuksen Säätiö
Diabetes Research Foundation of Finland
Helsinki University Hospital
Government Research Funds
Received: 28 January 2021
Accepted: 3 February 2021
First Online: 24 February 2021
Ethics approval and consent to participate
: Study protocol, patient information, and informed consent are approved by the Ethical Committee of the Hospital District of South-Western Finland (decision 100/1801/2018 §438). The study is conducted according to Good Clinical Practice and the Declaration of Helsinki. The participants receive the detailed study protocol and it is explained both orally and in written text that the participation to the study is voluntary and they have the right to withdraw from the study at any time without explaining the reason. Written informed consent for the study is obtained from all participants before the beginning of the study.
: The results will be presented as means ± SD in order to maintain anonymousity.
: None. The study has not received funding/assistance from a commercial organization.